{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:17:03Z","timestamp":1789607823340,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40261-023-01286-3","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T03:30:31Z","timestamp":1689651031000},"page":"551-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct00733902","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00744471","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00830063","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00863304","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00863772","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01089725","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00985621","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02697773","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02709486","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mark T.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Cornblath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Koltzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Gorson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn C.","family":"Pixton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Gaitonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Viktrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine R.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"4819","key":"1286_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.3306916","volume":"237","author":"R Levi-Montalcini","year":"1987","unstructured":"Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237(4819):1154\u201362.","journal-title":"Science"},{"issue":"10","key":"1286_CR2","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1097\/j.pain.0000000000001625","volume":"160","author":"M Schmelz","year":"2019","unstructured":"Schmelz M, Mantyh P, Malfait AM, Farrar J, Yaksh T, Tive L, et al. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019;160(10):2210\u201320.","journal-title":"Pain"},{"issue":"6","key":"1286_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/0092-8674(94)90378-6","volume":"76","author":"C Crowley","year":"1994","unstructured":"Crowley C, Spencer SD, Nishimura MC, Chen KS, Pitts-Meek S, Armanini MP, et al. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell. 1994;76(6):1001\u201311.","journal-title":"Cell"},{"issue":"1","key":"1286_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/ALN.0b013e31821b1ac5","volume":"115","author":"PW Mantyh","year":"2011","unstructured":"Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189\u2013204.","journal-title":"Anesthesiology"},{"issue":"1\u20132","key":"1286_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jns.2014.07.028","volume":"345","author":"MT Brown","year":"2014","unstructured":"Brown MT, Herrmann DN, Goldstein M, Burr AM, Smith MD, West CR, et al. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci. 2014;345(1\u20132):139\u201347.","journal-title":"J Neurol Sci"},{"issue":"7","key":"1286_CR6","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/art.37950","volume":"65","author":"MT Brown","year":"2013","unstructured":"Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. 2013;65(7):1795\u2013803.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1286_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jpain.2012.05.006","volume":"13","author":"MT Brown","year":"2012","unstructured":"Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012;13(8):790\u20138.","journal-title":"J Pain"},{"issue":"11","key":"1286_CR8","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3899\/jrheum.131294","volume":"41","author":"EF Ekman","year":"2014","unstructured":"Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014;41(11):2249\u201359.","journal-title":"J Rheumatol"},{"key":"1286_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/JPR.S191297","volume":"12","author":"L Tive","year":"2019","unstructured":"Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, et al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019;12:975\u201395.","journal-title":"J Pain Res"},{"issue":"1","key":"1286_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2019.8044","volume":"322","author":"TJ Schnitzer","year":"2019","unstructured":"Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA. 2019;322(1):37\u201348.","journal-title":"JAMA"},{"issue":"6","key":"1286_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","volume":"79","author":"F Berenbaum","year":"2020","unstructured":"Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020;79(6):800\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"434","key":"1286_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120184","volume":"15","author":"MT Brown","year":"2022","unstructured":"Brown MT, Sandroni P, Low PA, Gorson KC, Hunter DJ, Pixton GC, et al. Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis. J Neurol Sci. 2022;15(434): 120184.","journal-title":"J Neurol Sci"},{"key":"1286_CR13","unstructured":"Food and Drug Administration. Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee; 2021."},{"issue":"2","key":"1286_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.39492","volume":"68","author":"MC Hochberg","year":"2016","unstructured":"Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, et al. When Is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol. 2016;68(2):382\u201391.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"1286_CR15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/art.41674","volume":"73","author":"MC Hochberg","year":"2021","unstructured":"Hochberg MC, Carrino JA, Schnitzer TJ, Guermazi A, Walsh DA, White A, et al. Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis Rheumatol. 2021;73(7):1167\u201377.","journal-title":"Arthritis Rheumatol"},{"key":"1286_CR16","doi-asserted-by":"crossref","unstructured":"Pfizer. Pfizer reports third-quarter 2021 results; 2021. https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2021\/PFIZER-REPORTS-THIRD-QUARTER-2021-RESULTS\/default.aspx. Cited 11 Apr 2022.","DOI":"10.1016\/j.fopow.2021.11.012"},{"key":"1286_CR17","unstructured":"Eli Lilly and Company. Lilly reports robust third-quarter 2021 financial results as pipeline success strengthens future growth potential; 2021. https:\/\/investor.lilly.com\/static-files\/a0b77c52-a997-41c1-9534-5f465903a0b4. Cited 11 Apr 2022."},{"issue":"6","key":"1286_CR18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/ana.410080608","volume":"8","author":"PJ Dyck","year":"1980","unstructured":"Dyck PJ, Sherman WR, Hallcher LM, Service FJ, Obrien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol. 1980;8(6):590\u20136.","journal-title":"Ann Neurol"},{"issue":"6","key":"1286_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/pme.12677","volume":"16","author":"C Bramson","year":"2015","unstructured":"Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015;16(6):1163\u201376.","journal-title":"Pain Med"},{"issue":"11","key":"1286_CR20","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.41012","volume":"71","author":"P Dakin","year":"2019","unstructured":"Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIB\/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 2019;71(11):1824\u201334.","journal-title":"Arthritis Rheumatol"},{"key":"1286_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/annrheumdis-2020-217259","volume":"80","author":"P Dakin","year":"2021","unstructured":"Dakin P, Kivitz AJ, Gimbel JS, Skrepnik N, DiMartino SJ, Emeremni CA, et al. Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II\/III randomised clinical trial. Ann Rheum Dis. 2021;80:509\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1286_CR22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/art.39943","volume":"69","author":"P Sanga","year":"2017","unstructured":"Sanga P, Katz N, Polverejan E, Wang S, Kelly KM, Haeussler J, et al. Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase ii randomized, double-blind, placebo-controlled extension study. Arthritis Rheumatol. 2017;69(4):763\u201373.","journal-title":"Arthritis Rheumatol"},{"key":"1286_CR23","unstructured":"Janssen. Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain; 2016. https:\/\/www.jnj.com\/media-center\/press-releases\/janssen-announces-discontinuation-of-fulranumab-phase-3-development-program-in-osteoarthritis-pain#:~:text=TITUSVILLE%2C%20NJ%20(March%2031%2C,for%20fulranumab%20in%20osteoarthritis%20pain [cited 2023 May 21]."},{"key":"1286_CR24","unstructured":"Regeneron. Regeneron provides update on fasinumab program; 2020. https:\/\/investor.regeneron.com\/static-files\/e5ebab0a-f9b3-461c-aeaf-47fcb4e00242 [cited 2023 May 21]."},{"key":"1286_CR25","unstructured":"AstraZeneca. A Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee (BESPOKE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04675034."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01286-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01286-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01286-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T06:58:57Z","timestamp":1702796337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01286-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01286-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"25 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Pfizer and Eli Lilly and Company. Pfizer and Eli Lilly and Company contributed to the study design; Pfizer contributed to the management and collection of data. In their role as authors, employees of Pfizer and Eli Lilly were involved in the interpretation of data, preparation, review, and approval of the manuscript and the decision to submit for publication, along with their co-authors. The study sponsors approved the manuscript from an intellectual property perspective but had no right to veto the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DRC has served as a consultant for AlgoTX, Amgen Inc., Annexon Biosciences, Boehringer Ingelheim, Cigna Health Management Inc., CSL Behring, Grifols S.A., Johnson & Johnson, Nervosave, Nurobio, Octapharma AG, Passage Bio, Pfizer Inc., Pharnext SAS, Roche, Seattle Genetics Inc., and ValenzaBio. He sits on the Data Safety Monitoring Board for Anavex Life Sciences Corp, Passage Bio, PledPharma AB, Hansa Medical AB, and Mitsubishi Tanabe Pharma Corporation. Through Johns Hopkins University, he receives royalties for technology licensing from AstraZeneca Pharmaceuticals, LP, Genentech Inc., Levicept Inc., Seattle Genetics Inc., and Merrimack Pharmaceuticals. He sits on the Scientific Advisory Board for AlgoTx and Sinomab. MK is director of Neurophysiology Consulting Ltd and QTMS Science Ltd. During the past 5\u00a0years he has been an ad hoc consultant and the speaker bureau for Eli Lilly, GSK, Levicept, Marks & Clerk Law, Merck, Neursentis, Pfizer, Richmond Pharmaceuticals Ltd., and Roche. KG has served as a consultant for Argenx, Annexon, Janssen, Pfizer, and UCB Pharma. MTB, AH, GCP, PG, and CRW own stock in and are full-time employees of Pfizer. LV owns stocks in and is a full-time employee of Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. Seefor more information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The protocol for each clinical trial was approved by an institutional review board or independent ethics committee at each participating investigational center. The studies were conducted in compliance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice Guidelines.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All patients provided written informed consent before entering the studies.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent\u00a0to participate"}},{"value":"Mark Brown: Conceptualization, data curation, investigation, methodology, supervision, visualization, and writing (review and editing). David Cornblath: Investigation, supervision, and writing (review and editing). Martin Koltzenburg: Investigation, supervision, and writing (review and editing). Kenneth Gorson: Investigation, supervision, and writing (review and editing). Anne Hickman: Conceptualization, data curation, investigation, methodology, supervision, visualization, and writing (review and editing). Glenn C. Pixton: Conceptualization, data curation, formal analysis, investigation, methodology, supervision, visualization, and writing (review and editing). Puneet Gaitonde: Data curation, investigation, methodology, supervision, visualization, and writing (review and editing). Lars Viktrup: Conceptualization, methodology, supervision, visualization, and writing (review and editing). Christine West: Conceptualization, data curation, investigation, methodology, supervision, visualization, and writing (review and editing).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}